MedTrace Logo

Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis

NCT02897817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 471

Last updated 2018-03-29

No results posted yet for this study

Summary

The aim of this study is to evaluate, at 6 months, the rate of patients whose adherence to injectable MTX remained strong or improved according to patient-reported outcome.

Conditions

Sponsors & Collaborators

  • Nordic Pharma SAS

    lead INDUSTRY

Principal Investigators

  • René-Marc FLIPO, MD, Prof · CHU Hôpital Roger Salengro, LILLE

  • Eric SENBEL, MD · Doctor's Office, MARSEILLE

  • Sonia TROPE, Nurse · ANDAR

  • Hélène HERMAN-DEMARS, MD · NORDIC PHARMA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897817 on ClinicalTrials.gov